The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Key Takeaways Zepbound helped patients lose 50 pounds, compared to 33 pounds with WegovyThe study showed Zepbound users lost ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

Novo Nordisk (NYSE:NVO) shares dropped 5% in early trading on Monday after Eli Lilly (NYSE:LLY) released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy.

A 4.1 magnitude earthquake rattled eastern Tennessee and was felt all through the Southeastern states. 'The Big Weekend Show' panelists discuss President Donald Trump's new announcement.

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...